Loading stock data…
NVNO
$10.50+0.06 (+0.57%)
Market ClosedLast close May 1
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
enVVeno Medical Corporation in the Healthcare sector is trading at $10.50. The stock is currently near its 52-week low of $8.67, remaining 70.5% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why NVNO maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.50
Potential Upside
5%
Whystock Fair Value$11.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.26M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-85.03%
Volume
Today's trading volume
19,301
Recent News
Insider Buyers Lose Additional US$294k As enVVeno Medical Dips To US$6.5m
The recent price decline of 22% in enVVeno Medical Corporation's ( NASDAQ:NVNO ) stock may have disappointed insiders...
NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve
enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car
EnVVeno Medical Gets FDA Not-Approvable Letter for VenoValve; Shares Fall 70%
EnVVeno Medical (NVNO) shares were down 70% in recent Wednesday trading after the company said it re
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...